Modality
mRNA
MOA
EZH2i
Target
GPRC5D
Pathway
Epigenetic
GISTCRCADHD
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
Jun 2017
→ Feb 2030
Phase 3Current
NCT03887413
31 pts·ADHD
2017-12→2025-06·Terminated
NCT06318015
1,915 pts·GIST
2017-06→TBD·Active
NCT04749201
480 pts·ADHD
2017-10→2025-03·Recruiting
+1 more trial
4,209 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-03-061.1y agoPh3 Readout· ADHD
2025-06-189mo agoPh3 Readout· ADHD
2030-02-253.9y awayPh3 Readout· CRC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Active
P3
Recruit…
P3
Termina…
P3
Not yet…
Catalysts
Ph3 Readout
2025-03-06 · 1.1y ago
ADHD
Ph3 Readout
2025-06-18 · 9mo ago
ADHD
Ph3 Readout
2030-02-25 · 3.9y away
CRC
RecruitingActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03887413 | Phase 3 | ADHD | Terminated | 31 | EASI-75 |
| NCT06318015 | Phase 3 | GIST | Active | 1915 | CfB |
| NCT04749201 | Phase 3 | ADHD | Recruiting | 480 | DOR |
| NCT05620211 | Phase 3 | CRC | Not yet recr... | 1783 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 |